Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 47, 2016, Pages 13450-13455

  Li, Feng ^a   Fushima, Tomofumi ^b   Oyanagi, Gen ^b,e   Townley Tilson, H W Davin ^c,f   Sato, Emiko ^b   Nakada, Hironobu ^b   Oe, Yuji ^b   Hagaman, John R ^a   Wilder, Jennifer ^a   Li, Manyu ^c   Sekimoto, Akiyo ^b   Saigusa, Daisuke ^b   Sato, Hiroshi ^b   Ito, Sadayoshi ^b   Jennette, J Charles ^a   Maeda, Nobuyo ^a   Karumanchi, S Ananth ^d   Smithies, Oliver ^a   Takahashi, Nobuyuki ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b TOHOKU UNIVERSITY   (Japan)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e TOHOKU UNIVERSITY HOSPITAL   (Japan)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Fetal growth restriction; Nicotinamide; Placentation; Preeclampsia; sFLT1

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; ADENOSINE TRIPHOSPHATE; NICOTINAMIDE; NUCLEOTIDE; ASB4 PROTEIN, MOUSE; PLACENTAL GROWTH FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; EMBRYO; FEMALE; FETUS; HYPERTENSION; INTRAUTERINE GROWTH RETARDATION; MOTHER; MOUSE; NONHUMAN; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNTHESIS; ABNORMALITIES; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; COMPLICATION; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; EMBRYO DEATH; KIDNEY; MALE; METABOLISM; NEWBORN; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PLACENTA; PREVENTION AND CONTROL; SPONTANEOUS ABORTION; ULTRASTRUCTURE; UTERUS;

ABORTION, SPONTANEOUS; ALBUMINURIA; ANIMALS; ANIMALS, NEWBORN; BLOOD PRESSURE; BODY WEIGHT; DISEASE MODELS, ANIMAL; EMBRYO LOSS; FEMALE; FETAL GROWTH RETARDATION; HYPERTENSION; KIDNEY; MALE; MICE, INBRED C57BL; NIACINAMIDE; ORGAN SIZE; PLACENTA; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; UTERUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84996557457     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1614947113     Document Type: Article

References (32)

1. Levine RJ, et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350(7):672-683.
2. Li F, et al. (2012) eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype. J Am Soc Nephrol 23(4):652-660.
3. Murphy SR, LaMarca BB, Cockrell K, Granger JP (2010) Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 55(2):394-398.
4. Kingman M, Ruggiero R, Torres F (2009) Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 10(11):1847-1858.
5. Thai TL, Arendshorst WJ (2008) ADP-ribosyl cyclase and ryanodine receptors mediate endothelin ETA and ETB receptor-induced renal vasoconstriction in vivo. Am J Physiol Renal Physiol 295(2):F360-F368.
6. Knip M, et al.; European Nicotinamide Diabetes Intervention Trial Group (2000) Safety of high-dose nicotinamide: A review. Diabetologia 43(11):1337-1345.
7. Maynard SE, et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111(5):649-658.
8. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22(3):659-661.
9. Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group (2004) European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363(9413):925-931.
10. Hoffer A (1975) Nutrition and schizophrenia. Can Fam Physician 21(4):78-82.
11. Stillman IE, Karumanchi SA (2007) The glomerular injury of preeclampsia. J Am Soc Nephrol 18(8):2281-2284.
12. McMaster MT, Zhou Y, Fisher SJ (2004) Abnormal placentation and the syndrome of preeclampsia. Semin Nephrol 24(6):540-547.
13. Plaks V, et al. (2013) Matrix metalloproteinase-9 deficiency phenocopies features of preeclampsia and intrauterine growth restriction. Proc Natl Acad Sci USA 110(27):11109-11114.
14. Townley-Tilson WH, Wu Y, Ferguson JE, 3rd, Patterson C (2014) The ubiquitin ligase ASB4 promotes trophoblast differentiation through the degradation of ID2. PLoS One 9(2):e89451.
15. Reponen P, et al. (1995) 92-kDa type IV collagenase and TIMP-3, but not 72-kDa type IV collagenase or TIMP-1 or TIMP-2, are highly expressed during mouse embryo implantation. Dev Dyn 202(4):388-396.
16. Janatpour MJ, et al. (2000) Id-2 regulates critical aspects of human cytotrophoblast differentiation, invasion and migration. Development 127(3):549-558.
17. Duley L (2003) Pre-eclampsia and the hypertensive disorders of pregnancy. Br Med Bull 67:161-176.
18. von Dadelszen P, et al. (2000) Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: A meta-analysis. Lancet 355(9198):87-92.
19. Arendshorst WJ, Thai TL (2009) Regulation of the renal microcirculation by ryanodine receptors and calcium-induced calcium release. Curr Opin Nephrol Hypertens 18(1):40-49.
20. Rongvaux A, Andris F, Van Gool F, Leo O (2003) Reconstructing eukaryotic NAD metabolism. BioEssays 25(7):683-690.
21. Lim JH, et al. (2010) Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell 38(6):864-878.
22. Semenza GL (2000) HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88(4):1474-1480.
23. Harsem NK, Braekke K, Staff AC (2006) Augmented oxidative stress as well as antioxidant capacity in maternal circulation in preeclampsia. Eur J Obstet Gynecol Reprod Biol 128(1-2):209-215.
24. Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R (2014) Pre-eclampsia part 1: Current understanding of its pathophysiology. Nat Rev Nephrol 10(8):466-480.
25. Yamamoto T, et al. (2014) Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS One 9(6):e98972.
26. Kuo CJ, et al. (2001) Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 98(8):4605-4610.
27. Takahashi N, Boysen G, Li F, Li Y, Swenberg JA (2007) Tandem mass spectrometry measurements of creatinine in mouse plasma and urine for determining glomerular filtration rate. Kidney Int 71(3):266-271.
28. Fushima T, et al. (2016) Reduced Uterine Perfusion Pressure (RUPP) Model of Preeclampsia in Mice. PLoS One 11(5):e0155426.
29. Wang CH, et al. (2011) A modest decrease in endothelial NOS in mice comparable to that associated with human NOS3 variants exacerbates diabetic nephropathy. Proc Natl Acad Sci USA 108(5):2070-2075.
30. Oe Y, et al. (2016) Coagulation factor Xa and protease-activated receptor 2 as novel therapeutic targets for diabetic nephropathy. Arterioscler Thromb Vasc Biol 36(8):1525-1533.
31. Seifar RM, et al. (2013) Quantitative analysis of intracellular coenzymes in Saccharomyces cerevisiae using ion pair reversed phase ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr A 1311:115-120.
32. Nishiumi S, et al. (2012) A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One 7(7):e40459.